vision in San Antonio, Texas, who screened the first patient of the study. "There are few therapeutic options available today that slow the progression of CKD. Results from the Phase 2 BEAM trial suggest that bardoxolone methyl may improve measures of kidney function in patients with moderate to severe CKD and Type 2 diabetes. We look forward to further evaluating the drug candidate's effects on clinical outcomes in this patient population."
Final results from the 52-week Phase 2b BEAM study will be presented during a Late-Breaking Clinical Trials session on June 24 at the 2011 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Prague, Czech Republic.
About Chronic Kidney Disease
Chronic kidney disease (CKD) is a progressive loss of kidney function over a period of months or years that can be caused by a number of conditions, including diabetes and high blood pressure. CKD is a highly prevalent condition worldwide with numbers expected to rise over the next decade. In the United States there are more than 26 million patients with CKD, and more than 500,000 patients with ESRD.
About Bardoxolone Methyl
Bardoxolone methyl is a novel, first-in-class antioxidant inflammation modulator (AIM). Bardoxolone methyl is an Nrf2 activator, thereby inducing the transcription of genes that reduce oxidative stress and suppress important inflammatory mediators.
In January 2010, Reata and Kyowa Hakko Kirin (KHK) announced a licensing agreement providing KHK with the exclusive rights to develop and commercialize bardoxolone methyl in Japan and other selected Asian markets. In September 2010, Reata formed a strategic partnership with Abbott for the commercialization of bardoxolone methyl in other ex-U.S. markets. Reata retains exclusive rights to bardoxolone methyl in the U.S.
About Reata Pharmaceuticals
Reata Pharmaceuticals is the leader in discoPage: 1 2 3 Related medicine technology :1
. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month2
. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets3
. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.4
. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease5
. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test6
. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination7
. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis8
. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study9
. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial10
. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent11
. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award